




The relative strengths and weaknesses of Progenics Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Progenics Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 23% points. The greatest weakness of Progenics Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is 174%, being 64% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	63,732
Cost of Goods Sold	3,168
Intangible Assets	24,670
Liabilities, Current	22,068
Liabilities, Non-Current	46,915
Other Assets	19,380
Other Compr. Net Income	-43
Other Expenses	933
Other Liabilities	3,934
Other Net Income	-2,376
Other Revenues	34,986
Property and Equipment	11,688
Research and Development	49,223
Selling, General and Administrative Expense	47,838

Output Variable	Value in 1000 USD
Assets	119,470
Liabilities	72,917
Expenses	101,162
Revenues	34,986
Stockholders Equity	46,553
Net Income	-68,552
Comprehensive Net Income	-68,574
BaseVar	165,477
ECR before LimitedLiability	34%
Economic Capital Ratio	174%